A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Pembrolizumab
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms innovaTIL-04
Sponsors Iovance Biotherapeutics

03 Oct 2024 Status changed from recruiting to active, no longer recruiting.
28 Feb 2023 According to an Iovance Biotherapeutics media release, additional patients began enrolling to support a BLA in cervical cancer following progression on or after chemotherapy and pembrolizumab.
16 Aug 2022 Planned number of patients changed from 138 to 189.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com